Classement en actions
#5977
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on... Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Capitalisation boursière
$2.33B
Changement (1 jour)
11.43%
Changement (1 an)
408.10%
Échange Nanobiotix S.A. (NANO)
Le prix NANO avec la capitalisation boursière de B
Capitalisation boursière de Nanobiotix S.A.(NANO)
Capitalisation boursière: $2.33B
En August 2026, Nanobiotix S.A. a une capitalisation boursière de $2.33B. Cela fait de Nanobiotix S.A. la 5977th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Nanobiotix S.A. du 2012 au 2026
NANO par rapport au top 5 des plus populaires stocks
| Prix pour NANO |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.460T
|
+234,641.07%
|
|
|
|
|
$4.622T
|
+198,583.67%
|
|
|
|
|
$4.098T
|
+176,063.46%
|
|
|
|
|
$3.703T
|
+159,094.33%
|
|
|
|
|
$2.757T
|
+118,446.46%
|
